+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart

Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart

Clinical Science 117(4): 157-164

The aim of the present study was to verify whether plasma MMPs (matrix metalloproteinases) and TIMPs (tissue inhibitors of MMPs) could be used as potential markers of paraphysiological remodelling in the athlete's heart, and to correlate these matrix parameters with echocardiographic signs of LV (left ventricular) remodelling. Plasma MMP-2 and MMP-9 were measured by zymography, and TIMP-1 and TIMP-2 were measured by ELISA in 42 veteran marathoners with AH (athlete's heart), and in 25 sedentary healthy subjects (CTL). All subjects were submitted to a clinical examination and two-dimensional colour Doppler echocardiography together with the measurement of circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide); GGT (gamma-glutamyl transpeptidase) was evaluated as a marker of cardiovascular disease. Veteran athletes had a significant elevation in LV dimensions and calculated LV mass index. Diastolic and systolic functions were normal for both groups. MMP-9 levels were significantly lower in AH than in CTL subjects (56.9+/-4.3 compared with 119.4+/-21.5 m-units/l, P<0.01). There were significant differences in MMP-2 between the two groups, with a down-regulation in the AH subjects (182.5+/-16.8 units/ml in CTL compared with 117.1+/-9.1 units/ml in AH, P<0.01). MMP-2 and MMP-2/TIMP-2 were inversely correlated with myocardial indices of hypertrophy in AH and CTL subjects. AH and CTL subjects showed similar TIMP values. The results of the present study indicate that MMPs and TIMPs could represent potential biomarkers of adaptive heart remodelling in the athletes. In addition, the inverse correlation of the MMP-2/TIMP-2 system with echocardiographic signs of myocardial hypertrophy could represent a new diagnostic and prognostic indicator useful in the evaluation of cardiovascular risk in athletes.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055607683

Download citation: RISBibTeXText

PMID: 19196241

DOI: 10.1042/cs20080278

Related references

Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. European Heart Journal 26(13): 1333-1341, 2005

Altered gene expression of matrix-metalloproteinases and tissue inhibitors of metalloproteinases in patients supported by Left Ventricular Assist Devices. Journal of the American College of Cardiology 39(5 Suppl. A): 198A-199A, March 6, 2002

Excess of Matrix Metalloproteinases over their tissue inhibitors contributes to left ventricular structural remodeling during transition from hypertrophy to heart failure in hypertensive rats. Circulation 100(18 Suppl. ): I 565, Nov 2, 1999

Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling. Journal of Cellular and Molecular Medicine 15(4): 773-782, 2011

Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 and 2 as potential biomarkers for gestational hypertension. Singapore Medical Journal 53(10): 681-683, 2013

Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in pigmented villonodular synovitis suggests their potential role for joint destruction. Journal of Rheumatology 31(1): 110-119, 2004

Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. European Journal of Heart Failure 11(11): 1057-1062, 2010

Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113(17): 2089-2096, 2006

Dysregulation of matrix metalloproteinases and their tissue inhibitors is related to abnormality of left ventricular geometry and function in streptozotocin-induced diabetic minipigs. International Journal of Experimental Pathology 89(2): 125-137, 2008

Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 27(2): 93-100, 2004

Left ventricular remodelling and the athlete's heart: time to revisit the Morganroth hypothesis. Journal of Physiology 589(Pt 24): 5915, 2012

Urinary metalloproteinases and tissue inhibitors of metalloproteinases as potential early biomarkers for renal fibrosis in children with nephrotic syndrome. Medicine 97(8): E9964, 2018

Inhibition of matrix metalloproteinases An additional effect of ACE inhibitors on cardiac remodelling in heart failure?. European Heart Journal 21(Abstract Suppl.): 465, August-September, 2000

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. International Journal of Cardiology 151(2): 237-239, 2012

Clinical Investigation of Matrix Metalloproteinases, Tissue Inhibitors of Matrix Metalloproteinases, and Matrix Metalloproteinase/Tissue Inhibitors of Matrix Metalloproteinase Complexes and Their Networks in Apical Periodontitis. Journal of Endodontics 42(7): 1082-1088, 2017